All In Biotech

Drug Trial Radar · NCT05259722

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 513 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

513

Actual

Start

Jun 15, 2022

Primary completion

Nov 8, 2023

Study completion Dec 5, 2023

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Feb 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.

Conditions

  • Chronic Hand Eczema

Interventions

  • DelgocitinibDrug

    Cream for topical application 20 mg/g

  • ToctinoDrug

    1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HECSI Score From Baseline to Week 12Time frame: 12 weeks

Locations

102 sites in 10 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Graz, Austria

  • LEO Pharma Investigational Site

    Linz, Austria

  • LEO Pharma Investigational Site

    Linz, Austria

  • LEO Pharma Investigational Site

    Calgary, Canada

  • LEO Pharma Investigational Site

    Calgary, Canada

  • LEO Pharma Investigational Site

    Edmonton, Canada

  • LEO Pharma Investigational Site

    Edmonton, Canada

  • LEO Pharma Investigational Site

    Guelph, Canada

  • LEO Pharma Investigational Site

    London, Canada

  • LEO Pharma investigational site

    London, Canada

  • LEO Pharma investigational site

    Markham, Canada

  • LEO Pharma investigational site

    Niagara Falls, Canada

  • LEO Pharma Investigational Site

    North York, Canada

  • LEO Pharma investigational site

    Québec, Canada

  • LEO Pharma Investigational Site

    Red Deer, Canada

  • LEO Pharma investigational site

    Sherbrooke, Canada

  • LEO Pharma Investigational Site

    Antony, France

  • LEO Pharma Investigational Site

    Martigues, France

  • LEO Pharma Investigational Site

    Montpellier, France

  • LEO Pharma Investigational Site

    Nice, France

  • LEO Pharma investigational site

    Nice, France

  • LEO Pharma Investigational Site

    Reims, France

  • LEO Pharma Investigational Site

    Toulon, France

  • LEO Pharma Investigational Site

    Augsburg, Germany

  • LEO Pharma Investigational Site

    Berlin, Germany

  • LEO Pharma Investigational Site

    Berlin, Germany

  • LEO Pharma Investigational Site

    Bochum, Germany

  • LEO Pharma Investigational Site

    Bochum, Germany

  • LEO Pharma Investigational Site

    Bonn, Germany

  • LEO Pharma Investigational Site

    Darmstadt, Germany

  • LEO Pharma Investigational Site

    Dresden, Germany

  • LEO Pharma Investigational Site

    Erlangen, Germany

  • LEO Pharma Investigational Site

    Essen, Germany

  • LEO Pharma Investigational Site

    Frankfurt, Germany

  • LEO Pharma Investigational Site

    Friedrichshafen, Germany

  • LEO Pharma Investigational Site

    Gera, Germany

  • LEO Pharma Investigational Site

    Göttingen, Germany

  • LEO Pharma Investigational Site

    Halle, Germany

  • LEO Pharma Investigational Site

    Hamburg, Germany

  • LEO Pharma Investigational Site

    Heidelberg, Germany

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.